Therapeutic Antibodies Against Cancer
- 1 June 2012
- journal article
- review article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 26 (3) , 447-481
Abstract
No abstract availableKeywords
This publication has 226 references indexed in Scilit:
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escapeThe Journal of Pathology, 2010
- Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalThe Lancet Oncology, 2010
- A large library based on a novel (CH2) scaffold: Identification of HIV-1 inhibitorsBiochemical and Biophysical Research Communications, 2009
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941Cancer Cell, 2009
- Therapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon?2008
- Construction of a Large Phage-Displayed Human Antibody Domain Library with a Scaffold Based On a Newly Identified Highly Soluble, Stable Heavy Chain Variable DomainJournal of Molecular Biology, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodiesVirology, 2007
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004